The study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimer’s patients who take the therapy get worse after they stop…
The breakthrough Alzheimer's drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term.The study results on Leqembi, which Eisai shares with Biogen, also found that the health of Alzheimer's patients who take the therapy worsens after they stop treatment.
"Continuing treatment is important if you would like to maintain cognition and functionality longer," Kramer said.Kramer added that Eisai believes patients can eventually switch to a maintenance dose of Leqembi after roughly 18 to 24 months of treatment, which could be aEisai and Biogen are seeking regulatory approval for a once-monthly infusion of Leqembi, with a decision expected in January.
Patients who started on a placebo saw a slower rate of cognitive decline after switching to Leqembi at the 18-month mark. But their Alzheimer's disease was still worse than the group that started Leqembi earlier through the 36 months. Meanwhile, one phase two trial, called Study 201, examined patients who temporarily stopped treatment with Leqembi.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study saysThe study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimer’s patients who take the therapy get worse after they stop…
Read more »
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, EisaiThe committee said Leqembi's effect on delaying cognitive decline does not outweigh 'the risk of serious side effects associated with the medicine.'
Read more »
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, EisaiThe committee said Leqembi’s effect on delaying cognitive decline does not outweigh “the risk of serious side effects associated with the…
Read more »
European committee says Alzheimer's treatment Leqembi shouldn't get marketing approvalShares of Biogen slid Friday after a European regulatory committee said the Alzheimer’s treatment Leqembi should not receive marketing approval. The European Medicines Agency committee said concerns about the drug’s potential side effects outweigh the impact it has in slowing the fatal, mind-robbing disease.
Read more »
Shares of Japan's Eisai tumble after EU rejects Alzheimer's drugShares of Japan's Eisai tumble after EU rejects Alzheimer's drug
Read more »
Alzheimer's app could be key for newly diagnosed patients: 'Meets an important need'“It gives a prediction that is really tailored to each individual person,” said Pieter van der Veere, a physician-researcher at Alzheimer Centre Amsterdam.
Read more »